| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2017PLoSO..1271218H |
| P356 | DOI | 10.1371/JOURNAL.PONE.0171218 |
| P932 | PMC publication ID | 5300270 |
| P698 | PubMed publication ID | 28182774 |
| P50 | author | Bryan Coburn | Q58144514 |
| Josie Hughes | Q58876486 | ||
| Lindsey Falk | Q89242385 | ||
| P2093 | author name string | Jianhong Wu | |
| Amy Hurford | |||
| Andrew Morris | |||
| Kunquan Lan | |||
| Xi Huo | |||
| P2860 | cites work | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 |
| De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock | Q24198268 | ||
| Pseudomonas aeruginosa: all roads lead to resistance | Q28240246 | ||
| Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis | Q28303703 | ||
| Responses of Pseudomonas aeruginosa to antimicrobials | Q28305587 | ||
| "One-size-fits-all"? Optimizing treatment duration for bacterial infections | Q28478851 | ||
| Antibiotic Restriction Might Facilitate the Emergence of Multi-drug Resistance | Q28545750 | ||
| Steering Evolution with Sequential Therapy to Prevent the Emergence of Bacterial Antibiotic Resistance | Q28547894 | ||
| Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies | Q30620223 | ||
| Statistical epidemic modeling with hospital outbreak data | Q33365120 | ||
| Antibiotic control of antibiotic resistance in hospitals: a simulation study | Q33672358 | ||
| Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America | Q33688646 | ||
| Multilevel competing risk models to evaluate the risk of nosocomial infection | Q33750199 | ||
| Cycling empirical antibiotic therapy in hospitals: meta-analysis and models | Q33812804 | ||
| Selection of cross-resistance following exposure of Pseudomonas aeruginosa clinical isolates to ciprofloxacin or cefepime | Q33836617 | ||
| Informed switching strongly decreases the prevalence of antibiotic resistance in hospital wards | Q33842121 | ||
| Strategic interactions in multi-institutional epidemics of antibiotic resistance | Q33864106 | ||
| Assessment of empirical antibiotic therapy optimisation in six hospitals: an observational cohort study. | Q33925668 | ||
| Global sensitivity analysis for complex ecological models: a case study of riparian cottonwood population dynamics. | Q33966368 | ||
| Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec | Q33990521 | ||
| The magnitude and duration of Clostridium difficile infection risk associated with antibiotic therapy: a hospital cohort study | Q34089890 | ||
| Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship | Q34591740 | ||
| Modelling the transmission of healthcare associated infections: a systematic review | Q34786520 | ||
| Pseudomonas aeruginosa: resistance to the max | Q35084559 | ||
| Pseudomonas aeruginosa acquisition on an intensive care unit: relationship between antibiotic selective pressure and patients' environment | Q35566984 | ||
| Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients. | Q51004000 | ||
| The path of least resistance: aggressive or moderate treatment? | Q51033406 | ||
| Hospital-acquired infections--appropriate statistical treatment is urgently needed! | Q51163990 | ||
| Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. | Q51206353 | ||
| A network-based approach for resistance transmission in bacterial populations. | Q51793791 | ||
| Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. | Q54374662 | ||
| Epidemiology of Pseudomonas aeruginosa and risk factors for carriage acquisition in an intensive care unit | Q73179918 | ||
| [Are the prolonged carrier and interhospital clonal diffusion of serotype O12 multiresistant Pseudomonas aeruginosa connected?] | Q77116046 | ||
| The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group | Q77293121 | ||
| De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate | Q80430065 | ||
| Acquisition of Pseudomonas aeruginosa and its resistance phenotypes in critically ill medical patients: role of colonization pressure and antibiotic exposure | Q35608657 | ||
| Determinants of the Final Size and Case Rate of Nosocomial Outbreaks | Q35775814 | ||
| Epidemiological interpretation of antibiotic resistance studies - what are we missing? | Q35954276 | ||
| Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). | Q35975462 | ||
| Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial | Q36093598 | ||
| Multidrug therapy and evolution of antibiotic resistance: when order matters | Q36156421 | ||
| Analysis and presentation of cumulative antibiograms: a new consensus guideline from the Clinical and Laboratory Standards Institute | Q36737222 | ||
| Antimicrobial-associated risk factors for Clostridium difficile infection | Q37051298 | ||
| A modeling framework for the evolution and spread of antibiotic resistance: literature review and model categorization | Q37078552 | ||
| Impact of superinfection on hospital length of stay and costs in patients with ventilator-associated pneumonia | Q37387157 | ||
| How to measure the impacts of antibiotic resistance and antibiotic development on empiric therapy: new composite indices | Q37517286 | ||
| The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts. | Q37755968 | ||
| Contribution of mathematical modeling to the fight against bacterial antibiotic resistance | Q37862035 | ||
| Antimicrobial de-escalation strategies in hospitalized patients with pneumonia, intra-abdominal infections, and bacteremia | Q38107143 | ||
| Antibiotic de-escalation in bacteremic urinary tract infections: potential opportunities and effect on outcome | Q38215853 | ||
| Stress responses as determinants of antimicrobial resistance in Pseudomonas aeruginosa: multidrug efflux and more | Q38267242 | ||
| Antibiotic de-escalation in the ICU: how is it best done? | Q38359950 | ||
| A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit | Q38679343 | ||
| Linking antimicrobial prescribing to antimicrobial resistance in the ICU: before and after an antimicrobial stewardship program | Q39478816 | ||
| Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin | Q39817132 | ||
| Modelling the epidemiology of Escherichia coli ST131 and the impact of interventions on the community and healthcare centres | Q40807834 | ||
| Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin | Q42131963 | ||
| Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients | Q42276769 | ||
| Antimicrobial Stewardship Programs: Appropriate Measures and Metrics to Study their Impact | Q42554730 | ||
| Antimicrobial de-escalation in septic cancer patients: is it safe to back down? | Q43240867 | ||
| De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial | Q44019769 | ||
| De-escalation as a potential way of reducing antibiotic use and antimicrobial resistance in ICU. | Q44194515 | ||
| De-escalation of antimicrobial therapy for bacteraemia due to difficult-to-treat Gram-negative bacilli | Q44449024 | ||
| Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study. | Q44477142 | ||
| Complexity of resistance mechanisms to imipenem in intensive care unit strains of Pseudomonas aeruginosa. | Q45550772 | ||
| Risk factors for Pseudomonas aeruginosa acquisition in intensive care units: a prospective multicentre study | Q45847929 | ||
| De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study. | Q46744719 | ||
| Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study | Q49061695 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e0171218 | |
| P577 | publication date | 2017-02-09 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Benefits and unintended consequences of antimicrobial de-escalation: Implications for stewardship programs | |
| P478 | volume | 12 |
| Q50095636 | Effects of Clinically Meaningful Concentrations of Antipseudomonal β-Lactams on Time to Detection and Organism Growth in Blood Culture Bottles |
| Q61444360 | Positively interacting strains that co-circulate within a network structured population induce cycling epidemics of Mycoplasma pneumoniae |
| Q93270300 | The Relative Impact of Community and Hospital Antibiotic Use on the Selection of Extended-spectrum Beta-lactamase-producing Escherichia coli |
Search more.